<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36053951</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>782</StartPage><EndPage>792</EndPage><MedlinePgn>782-792</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26466</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Reactivation of HERV-K(HML-2) has been found in subsets of individuals with amyotrophic lateral sclerosis (ALS). This study examines the antibody response against HML-2 in ALS and analyzes its clinical relevance.</AbstractText><AbstractText Label="METHODS">Antibodies to HML-2 envelope (env) were analyzed using a peptide array for epitope mapping and by a peptide enzyme-linked immunosorbent assay (ELISA) in 242 healthy donors, and 243 ALS and 85 multiple sclerosis (MS) individuals. Extracellular levels of HML-2 were analyzed by digital polymerase chain reaction (PCR).</AbstractText><AbstractText Label="RESULTS">Antibodies in the sera of ALS individuals recognized more HML-2 env peptides compared to healthy controls (p&#x2009;&lt;&#x2009;0.0001). ALS individuals had higher levels of HML-2 than healthy donors (p&#xa0;=&#xa0;0.02) and higher antibody levels against a select HML-2 env peptide compared to healthy donors or individuals with multiple sclerosis (p&#x2009;&lt;&#x2009;0.0001). 55.14% of ALS compared to 21.16% of healthy donors and 13.10% of MS individuals had antibodies against the HML-2 peptide (AUC&#xa0;=&#xa0;0.769, p&#x2009;&lt;&#x2009;0.0001). Levels of extracellular HML-2 DNA in serum (p&#xa0;=&#xa0;0.02) and the number of HML-2 env peptides recognized by ALS sera (p&#xa0;=&#xa0;0.02) correlated with disease duration. Among ALS individuals, lower levels of HML-2 antibodies were associated with a definite diagnosis per EL Escorial criteria (p&#xa0;=&#xa0;0.03), and with a lower predicted (p&#xa0;=&#xa0;0.02) and observed survival (p&#xa0;=&#xa0;0.03).</AbstractText><AbstractText Label="INTERPRETATION">There is a differential antibody response against specific epitopes of HML-2 env in ALS and controls, suggesting epitope spreading, likely due to persistent antigenic exposure following reactivation of the viral genes. Low levels of antibodies to HML-2 env in ALS are associated with poor prognosis and decreased survival probability. ANN NEUROL 2022;92:782-792.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Montojo</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0664-3480</Identifier><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simula</LastName><ForeName>Elena Rita</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fathi</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4303-1993</Identifier><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahan</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosal</LastName><ForeName>Anubrata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and the Neurology Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and the Neurology Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS and the Neurology Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkahloun</LastName><ForeName>Abdel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kory</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norato</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sechi</LastName><ForeName>Leonardo A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Division of Microbiology and Virology, University of Sassari, Sassari, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Struttura Complessa Microbiologia e Virologia, Azienda Ospedaliera Universitaria Sassari, Sassari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Avindra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0927-5855</Identifier><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36053951</ArticleId><ArticleId IdType="doi">10.1002/ana.26466</ArticleId><ArticleId IdType="pmc">PMC9805205</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang T, Medynets M, Johnson KR, et al. Regulation of stem cell function and neuronal differentiation by HERV&#x2010;K via mTOR pathway. Proc Natl Acad Sci USA 2020;117:17842&#x2013;17853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395438</ArticleId><ArticleId IdType="pubmed">32669437</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews WD, Tuke PW, Al&#x2010;Chalabi A, et al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol 2000. Aug;61:527&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">10897073</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormick AL, Brown RH Jr, Cudkowicz ME, et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008. Jan 22;70:278&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">18209202</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele AJ, Al&#x2010;Chalabi A, Ferrante K, et al. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005. Feb 8;64:454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15699374</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGowan DJ, Scelsa SN, Imperato TE, et al. A controlled study of reverse transcriptase in serum and CSF of HIV&#x2010;negative patients with ALS. Neurology 2007;68:1944&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pubmed">17536052</ArticleId></ArticleIdList></Reference><Reference><Citation>Viola MV, Frazier M, White L, et al. RNA&#x2010;instructed DNA polymerase activity in a cytoplasmic particulate fraction in brains from Guamanian patients. J Exp Med 1975;142:483&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189894</ArticleId><ArticleId IdType="pubmed">49390</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Montojo M, Doucet&#x2010;O'Hare T, Henderson L, Nath A. Human endogenous retrovirus&#x2010;K (HML&#x2010;2): a comprehensive review. Crit Rev Microbiol 2018;44:715&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan KHY, Fu Y, Dzamko N, et al. Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Commun Med 2021;1:1&#x2013;11. 10.1038/s43856-021-00060-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-021-00060-w</ArticleId><ArticleId IdType="pmc">PMC8788987</ArticleId><ArticleId IdType="pubmed">35083468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer J, Harz C, Sanchez L, et al. Transcriptional profiling of HERV&#x2010;K(HML&#x2010;2) in amyotrophic lateral sclerosis and potential implications for expression of HML&#x2010;2 proteins. Mol Neurodegener 2018;13:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6091006</ArticleId><ArticleId IdType="pubmed">30068350</ArticleId></ArticleIdList></Reference><Reference><Citation>Garson JA, Usher L, Al&#x2010;Chalabi A, et al. Quantitative analysis of human endogenous retrovirus&#x2010;K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV&#x2010;K RNA in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2019;7:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421708</ArticleId><ArticleId IdType="pubmed">30885274</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep 2019;29:1164&#x2013;77 e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Lee MH, Henderson L, et al. Human endogenous retrovirus&#x2010;K contributes to motor neuron disease. Sci Transl Med 2015;7:307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol 2011;69:141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052883</ArticleId><ArticleId IdType="pubmed">21280084</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chen Y, Zhang N, Fan D. Human endogenous retrovirus K (HERV&#x2010;K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener 2021;23:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34151656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J, Rowe DB, Kiernan MC, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:595&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">31284774</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Montojo M, Fathi S, Norato G, et al. Inhibition of HERV&#x2010;K (HML&#x2010;2) in amyotrophic lateral sclerosis patients on antiretroviral therapy. J Neurol Sci 2021;423:117358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009857</ArticleId><ArticleId IdType="pubmed">33653604</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Curzio D, Gurm M, Turnbull M, et al. Pro&#x2010;inflammatory signaling upregulates a neurotoxic Conotoxin&#x2010;like protein encrypted within human endogenous retrovirus&#x2010;K. Cells 2020;9:1584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7407490</ArticleId><ArticleId IdType="pubmed">32629888</ArticleId></ArticleIdList></Reference><Reference><Citation>Arru G, Mameli G, Deiana GA, et al. Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases. Eur J Neurol 2018;25:1076&#x2013;e84.</Citation><ArticleIdList><ArticleId IdType="pubmed">29603839</ArticleId></ArticleIdList></Reference><Reference><Citation>Simula ER, Arru G, Zarbo IR, et al. TDP&#x2010;43 and HERV&#x2010;K envelope&#x2010;specific immunogenic epitopes are recognized in ALS patients. Viruses 2021;13:2301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8623164</ArticleId><ArticleId IdType="pubmed">34835107</ArticleId></ArticleIdList></Reference><Reference><Citation>Arru G, Galleri G, Deiana GA, et al. HERV&#x2010;K modulates the immune response in ALS patients. Microorganisms 2021;9:1784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8399181</ArticleId><ArticleId IdType="pubmed">34442863</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial world Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world Federation of Neurology Research Group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124:96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">11456302</ArticleId></ArticleIdList></Reference><Reference><Citation>Buus S, Rockberg J, Forsstrom B, et al. High&#x2010;resolution mapping of linear antibody epitopes using ultrahigh&#x2010;density peptide microarrays. Mol Cell Proteomics 2012;11:1790&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518105</ArticleId><ArticleId IdType="pubmed">22984286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley LA, Mezulis S, Yates CM, et al. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 2015;10:845&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298202</ArticleId><ArticleId IdType="pubmed">25950237</ArticleId></ArticleIdList></Reference><Reference><Citation>Willighagen E, Howard M. Fast and scriptable molecular graphics in web browsers without Java3D. Nat Preced 2007. 10.1038/npre.2007.50.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npre.2007.50.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan K, He Y, Fu Y, et al. Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Commun Med 2021;1:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788987</ArticleId><ArticleId IdType="pubmed">35083468</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlugt CL, Miller SD. Epitope spreading in immune&#x2010;mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002. Feb;2:85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9571257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005;52:2599&#x2013;2606.</Citation><ArticleIdList><ArticleId IdType="pubmed">16142758</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad K, Bachmann MP, Matsuura E, Shoenfeld Y. From animal models to human genetics: research on the induction and pathogenicity of autoantibodies. Autoimmun Rev 2005;4:178&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823504</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low&#x2010;density lipoprotein receptor&#x2010;deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003;48:2974&#x2013;2978.</Citation><ArticleIdList><ArticleId IdType="pubmed">14558104</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Baruch K. Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight&#x2010;off chronic neuroinflammation. J Autoimmun 2014;54:8&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">25199710</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, de Vito G, et al. Immune response in peripheral axons delays disease progression in SOD1(G93A) mice. J Neuroinflammation 2016;13:261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoles E, Hauben E, Palgi O, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001;21:3740&#x2013;3748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762728</ArticleId><ArticleId IdType="pubmed">11356861</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther 2014;6:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979082</ArticleId><ArticleId IdType="pubmed">24423082</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard JD, Kamel F. Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival. Epidemiol Rev 2015;37:55&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4325667</ArticleId><ArticleId IdType="pubmed">25365170</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham NS, Sharp DJ. Understanding neurodegeneration after traumatic brain injury: from mechanisms to clinical trials in dementia. J Neurol Neurosurg Psychiatry 2019;90:1221&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6860906</ArticleId><ArticleId IdType="pubmed">31542723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bye N, Turnley AM, Morganti&#x2010;Kossmann MC. Inflammatory regulators of redirected neural migration in the injured brain. Neurosignals 2012;20:132&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">22456466</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtin F, Perron H, Kromminga A, et al. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV&#x2010;Env protein. MAbs 2015;7:265&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623301</ArticleId><ArticleId IdType="pubmed">25427053</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Montojo M, Rodriguez&#x2010;Martin E, Ramos&#x2010;Mozo P, et al. Syncytin&#x2010;1/HERV&#x2010;W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. Eur J Immunol 2020;50:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">32012247</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer D, Forster M, Schichel T, et al. The neutralizing antibody GNbAC1 abrogates HERV&#x2010;W envelope protein&#x2010;mediated oligodendroglial maturation blockade. Mult Scler 2015;21:1200&#x2013;1203.</Citation><ArticleIdList><ArticleId IdType="pubmed">25480862</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner J, Bachani M, Malik N, et al. Neurotoxic properties of human endogenous retrovirus&#x2010;K envelope protein and detection in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Ann Neurol 2021;90:S213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9489628</ArticleId><ArticleId IdType="pubmed">35801347</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner JBM, Malik N, DeMarino C, et al. HERV&#x2010;K envelope in spinal fluid of amyotrophic lateral sclerosis is toxic. Ann Neurol 2022. 10.1002/ana.26452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26452</ArticleId><ArticleId IdType="pmc">PMC9489628</ArticleId><ArticleId IdType="pubmed">35801347</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y, Shodai A, Morimura T, et al. Elimination of TDP&#x2010;43 inclusions linked to amyotrophic lateral sclerosis by a misfolding&#x2010;specific intrabody with dual proteolytic signals. Sci Rep 2018;8:6030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902603</ArticleId><ArticleId IdType="pubmed">29662239</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Pandya D, Pasternack N, et al. Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis. Neurotherapeutics 2022;1&#x2013;17. 10.1007/s13311-022-01233-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01233-8</ArticleId><ArticleId IdType="pmc">PMC9587200</ArticleId><ArticleId IdType="pubmed">35415778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>